Sign in

You're signed outSign in or to get full access.

Tommy

Research Analyst at Goldman Sachs

No comprehensive professional profile for a Tommy working as an analyst at Goldman Sachs could be identified based on thorough searches of LinkedIn and related platforms. Multiple individuals named Tommy or Thomas are associated with Goldman Sachs, but none match the description of an equity research analyst with publicly available details on company coverage, performance metrics, or credentials. If additional details like full name, location, or department are provided, further research can be conducted.

Tommy's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership

Question · Q4 2025

Tommy inquired about the factors assumed in Voxzogo's guidance, particularly regarding new patient starts and potential switching in the context of upcoming competition, and BioMarin's confidence in establishing BMN 333 as the preferred option.

Answer

Brian Mueller, Chief Financial Officer, explained that the 2026 Voxzogo guidance reflects scenarios including competitive impact and market access renegotiations, aiming for high single-digit growth. Cristin Hubbard, Chief Commercial Officer, reiterated the focus on driving new patient starts in the 0-2 age group and protecting against switching. Greg Friberg, Chief R&D Officer, expressed confidence that BMN 333's superior growth profile, powered to detect a 2.25 cm/year increase, will differentiate it as the most active agent.

Ask follow-up questions

Fintool

Fintool can predict BIOMARIN PHARMACEUTICAL logo BMRN's earnings beat/miss a week before the call

News for Covered Companies

BioMarin Bets $4.8 Billion on Amicus to Create Rare Disease Powerhouse

BioMarin Bets $4.8 Billion on Amicus to Create Rare Disease Powerhouse

BMRNDec 19, 2025